TAKEDA-PHARMACEUTICAL
Takeda (TSE:4502/NYSE:TAK) today announced that for the seventh consecutive year, it has received global Top Employer® certification for 2024. Takeda is one of just 17 companies that received global recognition, and it was additionally certified as a Top Employer across 24 countries.
The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers 20 topics including people strategy, work environment, talent acquisition, learning, diversity & inclusion, well-being and more. Companies are evaluated on existing policies and practices.
“Our colleagues work hard to help patients around the world, which is why we focus on creating an exceptional people experience at Takeda,” said Lauren Duprey, chief human resources officer, Takeda. “Receiving this recognition from Top Employers Institute confirms that prioritizing talent, well-being, learning and diversity, equity and inclusion is the right approach – and that by doing so, we’re enabling our people to discover and deliver life-transforming treatments around the globe.”
“Exceptional times bring out the best in people and organizations, and we have witnessed this in our Top Employers Certification Program this year: an exceptional performance from the certified Top Employers 2024. Amongst this community of outstanding organizations, Takeda, has proven their commitment to their employees on a global scale,” said David Plink, chief executive officer, Top Employers Institute. “This consistency in people practices across the globe characterizes an exclusive group of companies that have achieved a global certification through the Top Employers Program. We are proud to announce and celebrate these companies and their achievement in 2024.”
Takeda excelled globally in the areas of ethics & integrity, purpose & values, business strategy, employer branding and organization & change. The full list of countries where Takeda was named a Top Employer is below:
- Asia Pacific: Australia, China, India, Japan, South Korea
- Europe: Austria, Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Slovakia, Spain, Switzerland, United Kingdom
- Latin America: Argentina, Brazil, Colombia, Mexico
- Middle East: Israel
- North America: Canada and United States
To learn more about Top Employers Institute and the Top Employers certification, please visit: https://www.top-employers.com.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we,” “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118372418/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium4.11.2025 16:04:00 CET | Press release
Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRIFirst-of-its-kind single intratumoral injection for MBC to the spineTreated lesions showed full bone regeneration with reconstitution of trabecular bone, and no skeletal related events; mean lesion defect volume decreased by 87.9% at day 180.Therapeutic spread extended to nearby non-treated lesions, also achieving complete response within the same vertebral body Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its abstract titled “Single Intratumoral Drug Injection Yields Complete Response (CR) in Metastatic Breast Cancer (MBC) Bone Lesions”, has been accepted and will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 10, 2025. The abstract
ID5 Acquires TrueData, Combining Strengths to Create the Most Comprehensive Identity Solution for Digital Advertising4.11.2025 16:00:00 CET | Press release
Acquisition creates a global privacy-focused identity powerhouse and enhances value for partners through expanded capabilities ID5, the market-leading ID provider for digital advertising, has today announced the acquisition of TrueData, a top-tier US-based identity graph company. The deal represents a major step forward in ID5’s growth strategy, significantly strengthening its presence in the US and broadening the value it can deliver to partners worldwide. ID5, recognized as a global leader in the alternative ID space, has built a strong foothold in the US, where the majority of its clients and revenue originate. By bringing in TrueData’s graph, the company is expanding its operations in the US and strengthening its Adaptive Identity technology with new datasets and expertise. The combination of TrueData’s graph and expertise with the GDPR compliant ID5 Graph, and its scaled alternative ID creates a unique proposition in the market, connecting offline data with the largest online reac
Westlake Announces Proposed Offering of Senior Notes4.11.2025 15:15:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of an underwritten public offering, subject to market and other conditions, of senior unsecured notes (the “Notes”) under its existing shelf registration statement. The timing of pricing and terms of the Notes are subject to market conditions and other factors. Westlake intends to use the net proceeds from the proposed public offering of the Notes to fund the repurchase of its outstanding 3.600% Senior Notes due 2026 (the “2026 Senior Notes”) pursuant to a concurrent cash tender offer (the “Tender Offer”) for any and all of the 2026 Senior Notes. Westlake anticipates using any remaining net proceeds to fund the purchase price of its pending acquisition of the global compounding solutions businesses of the ACI/Perplastic Group (the “ACI Acquisition”) and for general corporate purposes, including working capital management. The offering of the Notes is not contingent upon the successful completion of the Tende
Westlake Announces Cash Tender Offer4.11.2025 15:13:00 CET | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today the commencement of a cash tender offer to purchase (the “Offer”) any and all of the outstanding 3.600% Senior Notes due 2026 (the “Notes”) as set forth in the table below. The tender offer is being made solely pursuant to the terms and conditions set forth in an Offer to Purchase, dated November 4, 2025 (the “Offer to Purchase”). Holders of the Notes are urged to carefully read the Offer to Purchase before making any decision with respect to the tender offer. The tender offer is not conditioned on any minimum amount of the Notes being tendered. Subject to applicable law, Westlake may amend, extend or terminate the tender offer in its sole discretion. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offer to Purchase. Series of Notes CUSIP Numbers(1) Aggregate Principal Amount Outstanding U.S. Treasury Reference Security(2) Bloomberg Reference Page(2) Fixed Spread(3) 3.600% S
In-House Counsel Warn of Mounting Risks as Service of Process Volume Surges4.11.2025 15:00:00 CET | Press release
93% of in-house counsel say mass arbitration is increasing SOP risk and complexity59% report varying state requirements are driving compliance errors97% use AI for managing or analyzing SOP, yet 96% remain concerned about accuracy and speed The volume of service of process (SOP)—the legal procedure by which one party formally notifies another of a legal action—is surging across the U.S., amplifying operational pressure and compliance risk for in-house legal teams. This is according to a new nationwide study commissioned by CSC, industry-leading registered agent and compliance service provider. CSC surveyed 250 senior in-house counsel across the U.S. and found that rising SOP volume and growing concerns around data accuracy are intensifying both risk and workload pressure.1 Respondents cited data accuracy as a significant challenge to SOP management (61%), followed by rising SOP volume (56%). More than three-quarters (76%) said their departments are spending “too much” or “excessive” ti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom